Vermillion Appoints SVP of Sales and Marketing and Chief Commercial Officer
News Dec 20, 2013
Vermillion, Inc. has appointed Marian E. Sacco as senior vice president of sales and marketing and chief commercial officer.
Ms. Sacco is a proven leader in launching and building markets for innovative diagnostics to address key issues in improving women's health. She has more than 25 years of experience in product development, worldwide marketing, operations and sales management in both private and public companies.
Her focus on women's health began at Centocor Diagnostics where her achievements include the U.S. launch of CA125 used to monitor ovarian cancer recurrence.
More recently, she successfully led the commercial effort to build the global product market and laboratory service business for novel tests to manage pregnancy risks and infertility diagnostics as senior vice president, sales and marketing at Adeza BioMedical (acquired by Cytyc Corporation for more than $450 million, now part of Hologic).
"We are excited to add Marian's experience, energy and expertise in women's health and oncology to our team, as Vermillion expands its leadership role in commercializing OVA1 and future diagnostic tests," said Tom McLain, Vermillion's president and chief executive officer. "Marian has worked with us as a consultant in developing our commercial strategy. In this new role, she will draw on her proven track record in developing and executing sales and marketing strategies to expand awareness with physicians, patients and healthcare providers and drive increased use of OVA1."
Immediately prior to joining Vermillion, Ms. Sacco worked with numerous women's healthcare companies as a strategy and commercialization consultant. Her clients included both product and laboratory service companies focused on new, novel tests and technologies in genetics, pregnancy, reproductive health and oncology.
While at Adeza, Ms. Sacco oversaw both the strategic and day-to-day leadership of a global sales and marketing organization of more than 120 people. Over a 10-year period, her organization grew annual revenues from $1 million to $60 million and built the market for a unique test to aid in the management of preterm births.
By working with clinical thought leaders, gynecologists, nurses and health plans, she and her team successfully demonstrated that this test was clinically relevant, evidence based and cost effective and improved patient outcomes. This effort led to the introduction of new patient care guidelines in leading healthcare institutions, a critical step in building adoption, utilization and reimbursement.
Prior to Adeza, Ms. Sacco worked in senior commercial management roles at Behring Diagnostics, Chiron Diagnostics, and Ciba Corning Diagnostics. During this period, she developed and implemented novel oncology strategies including the launch of "companion diagnostics" in partnership with pharmaceutical business units.
Early in her career at Centocor Diagnostics, she managed U.S. sales, marketing and customer service for innovative cancer tests including launches of CA125, as well as CA15-3 for breast cancer monitoring.
Ms. Sacco holds a Master's degree in Radiopharmaceutical Science from Northeastern University and a Bachelors of Science degree in Chemistry/Biology from Marietta College.
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019